{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-22-000053","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.597121+00:00","generated_at":"2026-06-22T01:28:08.118815+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arvinas Q3 net loss widens to $66.2M; cash at $1.28B; on track for Phase 3 starts","bullets":["Net loss of $66.2M for Q3 2022 vs $46.8M in Q3 2021, driven by higher R&D and G&A costs.","Cash, cash equivalents and marketable securities were $1,276.2M as of Sept 30, 2022, sufficient beyond 2024.","R&D expenses nearly doubled to $77.5M, reflecting investment in platform and ER/AR programs.","On track to initiate two Phase 3 trials for ARV-471 in metastatic breast cancer by end of 2022.","Revenue from Pfizer collaboration drove revenues to $30.3M from $9.3M year-over-year."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-22-000053","json":"https://secwatch.observer/filing/0001655759-22-000053.json","markdown":"https://secwatch.observer/filing/0001655759-22-000053.md","text":"https://secwatch.observer/filing/0001655759-22-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575922000053/0001655759-22-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575922000053/arvn-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:28:08.118815+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ea8aedf55a72128ba277e21890abd29c43a0baa","claim":"ARVINAS, INC. reported financial results for quarter ended September 30, 2022.","evidence_excerpt":"On November 8, 2022 , Arvinas, Inc. announced its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1655759/000165575922000053/0001655759-22-000053-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}